Femasys makes women's health devices and diagnostics for fertility and permanent birth control, sold mainly to gynecologists and clinics. FEMY reports earnings on Tue, Nov 17, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 18 | Lake Street | Maintained | Buy | |
| Aug 14 | Maxim Group | Maintained | Buy |
Seasonality
How FEMY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in FEMY in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FEMY is in one of them and how their past FEMY trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered FEMY in an article yet. Here's the latest on the wider market.
About Femasys
Femasys is a women's health company based in Suwanee, Georgia, that makes medical devices and diagnostic products. Its fertility products include FemaSeed, a treatment that places sperm directly into the fallopian tube, along with FemSperm sperm preparation kits and FemVue, an ultrasound test of the fallopian tubes. It also offers FemBloc, a permanent birth control option that does not require surgery, along with the FemChec and FemCath products. Its customers are gynecologists, fertility clinics and other healthcare practitioners who treat women and couples.
- Headquarters
- Suwanee, GA